Prevalence Rates of Depression, Anxiety, and Suicidal Ideation in Patients with Ovarian cancer: A Systematic Review from 1977 to 2024.

Int J Psychiatry MedJun 13, 2025 (epub)

Tong Qiu, Tian Zhang, YiHan Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined observational studies reporting depression, anxiety, and suicidal ideation among people with ovarian cancer, with searches covering studies published through 30 June 2024. Across 31 studies involving 8,315 patients, estimated prevalence was 35% for depression and 37% for anxiety. The review also reported suicidal ideation prevalence of 32% in China. Depression prevalence was highest in Asia and lowest in Oceania; depression and anxiety prevalence rose considerably worldwide after 2000 and then gradually stabilized.

Key findings

  • Across 31 studies and 8,315 patients, depression prevalence was 35% and anxiety prevalence was 37%.
  • In China, suicidal ideation prevalence among patients with ovarian cancer was 32%.
  • Depression prevalence was highest in Asia and lowest in Oceania.
  • Depression and anxiety prevalence increased considerably worldwide after 2000 and gradually stabilized thereafter.

Why it matters

The review indicates that depression and anxiety affect more than one-third of the ovarian cancer populations represented in the included studies. These estimates highlight a substantial mental health burden alongside cancer care and point to the need for better evidence on incidence, regional variation, comorbidities, and effective approaches to care.

What to keep in mind

The review included observational studies, and the abstract does not report pooled uncertainty estimates or explain how differences in assessment scales and study populations affected prevalence estimates.

Source

Published in Int J Psychiatry Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.